$11.02▴ 2.51%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$4.47MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+28.4%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
ImmuCell Corporation is pre-profit. It generates operating cash even though it has no reported profit yet. Revenue is growing strongly year over year. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$-0.07
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-1.8%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$29.93M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.